Oracea

Rocky Mountain Spotted Fever, Acinetobacter Infections, Ureaplasma Infections + 61 more

Treatment

93 FDA approvals

20 Active Studies for Oracea

What is Oracea

Doxycycline

The Generic name of this drug

Treatment Summary

Doxycycline is a type of antibiotic used to treat a wide range of bacterial infections. It is derived from oxytetracycline and is a second-generation tetracycline, meaning it has lower levels of toxicity than the first-generation of tetracyclines. The effectiveness of doxycycline in treating an infection depends on the results of an antibiotic susceptibility test.

Vibramycin Hyclate

is the brand name

image of different drug pills on a surface

Oracea Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Vibramycin Hyclate

Doxycycline

1967

728

Approved as Treatment by the FDA

Doxycycline, otherwise known as Vibramycin Hyclate, is approved by the FDA for 93 uses such as Primary Syphilis and Upper Respiratory Tract Infection .

Primary Syphilis

Upper Respiratory Tract Infection

Streptococcus Pneumoniae Infections

Staphylococcus (S.) Aureus Infection

Anal chlamydia infection

Communicable Diseases

Clostridium difficile Infection

Klebsiella Infections

Chlamydia Infections

Severe Acne

Intestinal Amebiasis

Chlamydial Urethritis

Genus Chlamydia

Actinomycosis

Secondary Syphilis

Rickettsialpox

Cholera (Disorder)

Campylobacter Infections

Mycoplasma Pneumoniae

Inclusion conjunctivitis

Necrotizing ulcerative gingivostomatitis

Chlamydia Infections

Urethritis

Ureaplasma urethritis

Listeria infection

Urinary Tract Infections

Bacteriological Techniques

Relapsing fever caused by Borrelia recurrentis

Campylobacter Infection

Tick-borne fever

Plasmodium Infections

Skin Infections

Chlamydia trachomatis

Typhus, Endemic Flea-Borne

Communicable Diseases

Chlamydial cervicitis

Haemophilus Influenzae Infections

Calymmatobacterium granulomatis

Lymphogranuloma Venereum

Dysentery, Bacillary

Fever

Gonorrhea

Bartonella Infections

Acne Vulgaris

Q Fever

Acinetobacter Infections

Ureaplasma Infections

Communicable Diseases

Uterine Cervicitis

Tularemia

Typhus infections

Epididymo-orchitis gonococcal

Trachoma

Neisseria Gonorrhoeae Infection

Rocky Mountain Spotted Fever

Bartonella bacilliformis infections

Malaria

Bacterial Infection caused by Enterobacter aerogenes

Relapsing Fever

Yaws

Chancroid

Amebic colitis

Brucellosis

Used to treat Brucellosis in combination with Streptomycin

Recurrent Upper and Lower Respiratory Tract Infections (RTIs)

Plague

Chlamydia trachomatis

Cat-Scratch Disease

Shigella Infection

inhaled anthrax caused by Bacillus anthracis

Pneumococcal Infections

Clostridium Infections

Common Cold

Brucellosis

Used to treat Brucellosis in combination with Streptomycin

Trachoma

Plague

Urethritis

Acinetobacter Infections

Yersinia pestis

Psittacosis

Chlamydia psitacci infection

Ureaplasma Infections

Infection Due to Escherichia Coli

Trachoma inclusion conjunctivitis

Listeriosis

Yaws

Relapsing Fever

Vibrio Cholerae Infection

Disease

Haemophilus ducreyi infection

Tularemia

prophylaxis of Malaria

Respiratory Tract Infections

Granuloma Inguinale

Effectiveness

How Oracea Affects Patients

Doxycycline is an antibiotic that helps stop the growth of bacteria, and works by preventing bacteria from making proteins. It is a lipophilic drug, meaning it can pass through multiple layers of cells, and has a wide range of effectiveness against both gram-positive and gram-negative bacteria. It also has anti-parasitic and anti-inflammatory properties, and has been used to treat various inflammatory skin conditions.

How Oracea works in the body

Doxycycline prevents bacteria from making proteins they need to survive. It does this by blocking the molecules that attach to the ribosome of the cell, which is like a factory for making proteins. Doxycycline also stops inflammation by preventing calcium from helping create microtubules and keeping white blood cells from gathering at the site of inflammation. Additionally, it stops an enzyme that produces a molecule that causes inflammation.

When to interrupt dosage

The measure of Oracea is contingent upon the diagnosed state, including Urethritis, Chlamydia trachomatis and Respiratory Tract Infections. The dose likewise deviates in accordance with the technique of delivery (e.g. Capsule or Syrup - Oral) featured in the table underneath.

Condition

Dosage

Administration

Epididymo-orchitis gonococcal

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral, Capsule, extended release, Powder - Intravenous, Powder, Powder, for suspension, Syrup, Syrup - Oral, Powder, for suspension - Oral, Kit - Oral, For suspension - Oral, Kit, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Cat-Scratch Disease

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral, Capsule, extended release, Powder - Intravenous, Powder, Powder, for suspension, Syrup, Syrup - Oral, Powder, for suspension - Oral, Kit - Oral, For suspension - Oral, Kit, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Chlamydia Infections

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral, Capsule, extended release, Powder - Intravenous, Powder, Powder, for suspension, Syrup, Syrup - Oral, Powder, for suspension - Oral, Kit - Oral, For suspension - Oral, Kit, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Psittacosis

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral, Capsule, extended release, Powder - Intravenous, Powder, Powder, for suspension, Syrup, Syrup - Oral, Powder, for suspension - Oral, Kit - Oral, For suspension - Oral, Kit, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Relapsing Fever

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral, Capsule, extended release, Powder - Intravenous, Powder, Powder, for suspension, Syrup, Syrup - Oral, Powder, for suspension - Oral, Kit - Oral, For suspension - Oral, Kit, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Bacteriological Techniques

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral, Capsule, extended release, Powder - Intravenous, Powder, Powder, for suspension, Syrup, Syrup - Oral, Powder, for suspension - Oral, Kit - Oral, For suspension - Oral, Kit, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Tularemia

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral, Capsule, extended release, Powder - Intravenous, Powder, Powder, for suspension, Syrup, Syrup - Oral, Powder, for suspension - Oral, Kit - Oral, For suspension - Oral, Kit, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Clostridium difficile Infection

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral, Capsule, extended release, Powder - Intravenous, Powder, Powder, for suspension, Syrup, Syrup - Oral, Powder, for suspension - Oral, Kit - Oral, For suspension - Oral, Kit, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Klebsiella Infections

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral, Capsule, extended release, Powder - Intravenous, Powder, Powder, for suspension, Syrup, Syrup - Oral, Powder, for suspension - Oral, Kit - Oral, For suspension - Oral, Kit, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Haemophilus ducreyi infection

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral, Capsule, extended release, Powder - Intravenous, Powder, Powder, for suspension, Syrup, Syrup - Oral, Powder, for suspension - Oral, Kit - Oral, For suspension - Oral, Kit, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Pneumococcal Infections

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral, Capsule, extended release, Powder - Intravenous, Powder, Powder, for suspension, Syrup, Syrup - Oral, Powder, for suspension - Oral, Kit - Oral, For suspension - Oral, Kit, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Brucellosis

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral, Capsule, extended release, Powder - Intravenous, Powder, Powder, for suspension, Syrup, Syrup - Oral, Powder, for suspension - Oral, Kit - Oral, For suspension - Oral, Kit, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Actinomycosis

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral, Capsule, extended release, Powder - Intravenous, Powder, Powder, for suspension, Syrup, Syrup - Oral, Powder, for suspension - Oral, Kit - Oral, For suspension - Oral, Kit, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Primary Syphilis

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral, Capsule, extended release, Powder - Intravenous, Powder, Powder, for suspension, Syrup, Syrup - Oral, Powder, for suspension - Oral, Kit - Oral, For suspension - Oral, Kit, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Gonorrhea

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral, Capsule, extended release, Powder - Intravenous, Powder, Powder, for suspension, Syrup, Syrup - Oral, Powder, for suspension - Oral, Kit - Oral, For suspension - Oral, Kit, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Secondary Syphilis

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral, Capsule, extended release, Powder - Intravenous, Powder, Powder, for suspension, Syrup, Syrup - Oral, Powder, for suspension - Oral, Kit - Oral, For suspension - Oral, Kit, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Rickettsialpox

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral, Capsule, extended release, Powder - Intravenous, Powder, Powder, for suspension, Syrup, Syrup - Oral, Powder, for suspension - Oral, Kit - Oral, For suspension - Oral, Kit, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous

inhaled anthrax caused by Bacillus anthracis

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral, Capsule, extended release, Powder - Intravenous, Powder, Powder, for suspension, Syrup, Syrup - Oral, Powder, for suspension - Oral, Kit - Oral, For suspension - Oral, Kit, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Listeriosis

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral, Capsule, extended release, Powder - Intravenous, Powder, Powder, for suspension, Syrup, Syrup - Oral, Powder, for suspension - Oral, Kit - Oral, For suspension - Oral, Kit, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Urinary Tract Infections

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release - Oral, Capsule, extended release, Powder - Intravenous, Powder, Powder, for suspension, Syrup, Syrup - Oral, Powder, for suspension - Oral, Kit - Oral, For suspension - Oral, Kit, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Warnings

Oracea Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Doxycycline may interact with Pulse Frequency

Severe Hypersensitivity Reactions

Do Not Combine

Doxycycline may interact with Pulse Frequency

There are 20 known major drug interactions with Oracea.

Common Oracea Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be decreased when combined with Doxycycline.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Doxycycline.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Doxycycline.

Alpelisib

Major

The metabolism of Alpelisib can be decreased when combined with Doxycycline.

Amdinocillin

Major

The therapeutic efficacy of Amdinocillin can be decreased when used in combination with Doxycycline.

Oracea Toxicity & Overdose Risk

The lowest toxic dose of doxycycline in rats is 2000 mg/kg, 1870 mg/kg in mice, and 500 mg/kg in dogs. If someone overdoses on doxycycline, they should stop taking it and get medical help. Dialysis will not reduce the amount of drug in the body, so it will not help with an overdose.

image of a doctor in a lab doing drug, clinical research

Oracea Novel Uses: Which Conditions Have a Clinical Trial Featuring Oracea?

34 active studies are currently being conducted to assess the efficacy of Oracea in combating Haemophilus Influenzae Infections, Respiratory Tract Infections and Amebic Colitis.

Condition

Clinical Trials

Trial Phases

Plague

0 Actively Recruiting

Plague

0 Actively Recruiting

Epididymo-orchitis gonococcal

0 Actively Recruiting

Lymphogranuloma Venereum

0 Actively Recruiting

Gonorrhea

0 Actively Recruiting

Urinary Tract Infections

9 Actively Recruiting

Not Applicable, Phase 4, Early Phase 1

Chlamydia trachomatis

0 Actively Recruiting

Pneumococcal Infections

0 Actively Recruiting

Urethritis

0 Actively Recruiting

Typhus, Endemic Flea-Borne

0 Actively Recruiting

Clostridium difficile Infection

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

Chlamydia Infections

0 Actively Recruiting

inhaled anthrax caused by Bacillus anthracis

0 Actively Recruiting

Calymmatobacterium granulomatis

0 Actively Recruiting

Haemophilus Influenzae Infections

0 Actively Recruiting

Chancroid

0 Actively Recruiting

Klebsiella Infections

0 Actively Recruiting

Rosacea

2 Actively Recruiting

Early Phase 1, Phase 2

Rocky Mountain Spotted Fever

0 Actively Recruiting

Oracea Reviews: What are patients saying about Oracea?

5

Patient Review

3/14/2015

Oracea for Severe Difficult to Treat Nodular Rosacea

Oracea was a godsend for me. I had been struggling with Rosacea for years and tried everything to no avail. But this medication finally helped clear up my skin and I haven't had any issues since.

5

Patient Review

9/26/2013

Oracea for Severe Difficult to Treat Nodular Rosacea

Oracea has been effective for me in clearing my face. I use it together with Finacea, and it's worked well for me. The only downside is that as soon as I try to lower the dose (at least 3 times per week), all of my bumps and pimples return. It looks like I'll have to take it for as long as I can afford it!

5

Patient Review

8/15/2013

Oracea for Severe Difficult to Treat Nodular Rosacea

I've been using this treatment for three months now and have definitely seen an improvement. I'm less stressed in general, and when I do get stressed, the bumps aren't as bad as they used to be.

5

Patient Review

10/2/2012

Oracea for Severe Difficult to Treat Nodular Rosacea

This drug has been a complete wonder for me, it's helped with the redness of my rosacea immensely.

4.7

Patient Review

3/30/2014

Oracea for Severe Difficult to Treat Nodular Rosacea

I've been using this treatment for over five years to manage my Rosacea. It's been incredibly effective; however, I have to be careful about when I eat and drink (which can be annoying). All in all, though, it's a small price to pay for such good results. I haven't been able to find any information on long-term effects but, so far, so good.

4

Patient Review

1/12/2012

Oracea for Severe Difficult to Treat Nodular Rosacea

I find this to be a very effective treatment with no notable side effects. The price is high, but there are discounts available. It can take some time to work, but it's worth being patient. In my case, it worked great and I haven't experienced any issues since stopping the treatment.

2.7

Patient Review

2/2/2013

Oracea for Severe Difficult to Treat Nodular Rosacea

After taking Oracea and metronidazole cream as prescribed by my dermatologist, my skin started flaking off within two days. I called the doctor and they said to stop taking the metro cream. However, after reading comments online, I now realize it was the Oracea that caused the problems. I also had an outbreak on my chest and neck and terrible itching. The allergist took me off pravastatin and the redness went away along with most of the skin problems! Why don't doctors warn you about potential side effects??????

2.3

Patient Review

11/20/2012

Oracea for Severe Difficult to Treat Nodular Rosacea

I was really excited to try this treatment because my dermatologist made it sound like a total game changer for people with Rosacea. And while I did see some improvement after taking it for a few days, it wasn't worth the awful side effects I experienced. 10% just isn't enough when the cost is so high.

2.3

Patient Review

1/17/2013

Oracea for Severe Difficult to Treat Nodular Rosacea

I have seen zero benefits from this pill, and my acne is actually worse than before. Additionally, it was incredibly expensive; I refused to renew the prescription after learning that one month would cost over $1,000.

2

Patient Review

3/31/2013

Oracea for Severe Difficult to Treat Nodular Rosacea

After a year of use, I haven't seen any improvement in my condition. If anything, it's gotten worse.

1.7

Patient Review

2/21/2012

Oracea for Severe Difficult to Treat Nodular Rosacea

My rosacea symptoms actually got worse while taking this medication. I had a few initial days where it seemed to be helping, but then things took a turn for the worse. I also experienced some pretty unpleasant side effects like diarrhea, dry eyes and blurred vision, vaginal yeast infection, itching all over my body, bloating and weight gain, dizziness, and fatigue. Overall, not a great experience.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about oracea

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of Oracea?

"If you experience any of the following symptoms, you may be allergic to this medication: nausea, diarrhea, upset stomach, headache, skin rash, itching, and vaginal itching or discharge."

Answered by AI

How long should you take Oracea?

"Oracea should not be used to treat or prevent infections. Its efficacy beyond 16 weeks is unknown."

Answered by AI

What is Oracea prescribed for?

"The medication ORACEA® is only effective in treating the inflammatory lesions of rosacea, not the redness. It comes in the form of capsules, each containing 40 mg of doxycycline. ORACEA is intended for use by adult patients only."

Answered by AI

Are doxycycline and Oracea the same thing?

"ORACEA® (doxycycline, USP) 40mg* Capsules contains a low dose of doxycycline, which does not work by killing bacteria like traditional antibiotic doses."

Answered by AI

Clinical Trials for Oracea

Image of University of North Carolina in Chapel Hill, United States.

BLTR vs B-RAP for Trichiasis

18+
All Sexes
Chapel Hill, NC

The primary objective of this randomized clinical trial is to determine whether repeat trichiasis surgery performed with Bevel-Rotate Advancement Procedure (B-RAP) improves surgical success compared to Bilamellar Tarsal Rotation (BLTR) among a group of 8-10 TT surgeons in Tanzania. The study aims to enroll 1,000 individuals with PTT. The primary outcome is repeat PTT within one year after surgery. Additionally, the study will assess eyelid contour abnormalities and how they change over a two-year period as well as patient reported outcomes. If this project is successful in improving surgical outcomes, it could change the approach to treating PTT globally. Individuals with trichiasis have a significantly reduced quality of life; correcting their trichiasis long-term has the potential to improve their quality of life and their family members' quality of life considerably.

Waitlist Available
Has No Placebo

University of North Carolina

Emily Gower, PhD

Image of Children's of Alabama in Birmingham, United States.

Antibiotic Duration for Infections in Children

60 - 17
All Sexes
Birmingham, AL

Infections like pneumonia, skin and soft tissue infection (also called SSTI or cellulitis), and urinary tract infections (UTI) are some of the most common reasons children get admitted to the hospital. All three of these conditions require antibiotics for treatment. Although antibiotics are needed to treat the infection and help children feel better, taking them longer than needed can negatively impact children and their families. Negative impacts include things like the burdens of taking more medications and medication side effects. There are guidelines (instructions) from expert medical organizations that suggest the number of days children need antibiotics, but they give a wide range (between 5 and 14 days). Unfortunately, these guidelines are not based on high-quality studies. National data suggests that doctors often choose on the higher end of this range when writing prescriptions for children in the hospital. Our three caregiver co-investigators, other parents of hospitalized children, doctors, other care providers, and researchers, all believe that additional study is needed to determine the best length of antibiotic treatment that weighs both the benefits and harms of antibiotics. The goal of our study is to understand if 5 total days of antibiotic treatment compared to 10 total days of antibiotic treatment is better for children who have been in the hospital for pneumonia, SSTI, or UTI. We will study this question through a randomized control trial. In other words, half of the children will receive 5-days of antibiotics and the other half will receive 10-days of antibiotics. Children in this study (and their caregivers) will not know how many days of antibiotics they will receive to cure their infection because some children will take a placebo (or a pill without antibiotics in it). Only the pharmacy will know if a child is getting antibiotic or placebo (for days 6-10 of treatment). During the first phase of the trial (feasibility phase), 4 hospitals will enroll children in the study. We plan on enrolling 50 patients during this phase. We are starting with just 4 hospitals, so our study team can create and update our study plans if needed. We will closely review information about how many patients and families agree to participate, and if they have any trouble completing any part of the study. We will also interview families to understand the choice to participate in the study, the choice not to participate in the study, and what it is like to be in the study. During the second study phase, we will enroll 1150 more patients across all 11 hospitals. Families will complete short, daily surveys until the 15th day after they started antibiotics, then a larger survey at day 15, at day 20, and at day 30. These surveys will ask about the child's symptoms and recovery from their illness, how the antibiotics are making them feel, and if they had to go back to their doctor, emergency room, or hospital. The answers to these questions will be combined to measure how well the child did, balancing feeling better and having bad effects from the antibiotics. We will use mathematical tests to determine which antibiotic duration is better for treating these illnesses. We will complete other mathematical tests to see if all children should receive the same length of antibiotics or if certain children should be prescribed shorter courses and others longer courses.

Phase 4
Waitlist Available

Children's of Alabama (+9 Sites)

Sunitha V Kaiser, MD, MSc

Image of Medstar National Rehabilitation Hospital in Washington D.C., United States.

Lactobacillus Crispatus for Urinary Tract Infection

18+
All Sexes
Washington D.C., United States

The goal of this clinical trial is to determine whether Lactobacillus crispatus strains isolated from the lower urinary tracts of adult women can be used as an antibiotic-sparing treatment for urinary symptoms and urinary tract infection (UTI) among adults with neurogenic lower urinary tract dysfunction (NLUTD). The main question\[s\] it aims to answer are: 1. To identify soluble bactericidal compounds produced by urinary isolates of L. crispatus that kill uropathogenic E. coli (UPEC). 2. To determine if intravesical instillation of L. crispatus is safe and well tolerated in adults with NLUTD due to SCI who use intermittent catheterization (IC). If there is a comparison group: Researchers will compare L. Crispatus to standard care saline to see if there is a difference in urinary symptoms and urinary microbiome. Participants will be asked to complete daily symptom surveys, complete 2 bladder instillations, and collect, freeze, and return 14 urine samples.

Phase < 1
Recruiting

Medstar National Rehabilitation Hospital

Suzanne Groah, MD

Have you considered Oracea clinical trials?

We made a collection of clinical trials featuring Oracea, we think they might fit your search criteria.
Go to Trials
Image of Baylor College of Medicine in Houston, United States.

Educational Tool for Urinary Tract Infections

18+
All Sexes
Houston, TX

Urine culture is the most common microbiological test in the outpatient setting in the United States. Unfortunately, contamination during collection is prevalent and undermines test accuracy, leading to incorrect diagnosis, unnecessary treatment, wasted laboratory resources, and inflated costs. Unnecessary antibiotic treatment increases the risk of developing antimicrobial resistance, one of the most serious threats to patients and public health. The goal of this clinical trial is to test whether a bilingual (English and Spanish) educational intervention, an animated video and pictorial flyer, can reduce urine culture contamination and associated inappropriate antibiotic use in adult patients visiting safety-net primary care clinics. The main questions it aims to answer are: 1. Does providing patients with a bilingual educational intervention reduce urine culture contamination rates? 2. Does the intervention lead to fewer unnecessary urinary antibiotic prescriptions? 3. Does providing patients with a bilingual educational intervention reduce contaminated urinalyses? Researchers will compare patients randomized to receive the educational intervention (video and flyer) to those receiving usual care to see if the intervention improves urine collection accuracy and reduces inappropriate antibiotic use. Participants will watch a short, animated video with step-by-step instructions for proper midstream clean-catch urine (MSCC) collection, receive a pictorial flyer (with stills from the video) reinforcing the instructions, and provide a urine sample for culture. Hypothesis: patients who receive the educational intervention will have: lower urine culture contamination rates (primary outcome), fewer urinary antibiotic prescriptions (secondary outcome), and fewer contaminated urinalyses (secondary outcome). The objectives are to (1) develop educational tools: Create an animated video and pictorial flyer with step-by-step urine collection instructions for women and men, developed through an iterative, stakeholder-engaged process, (2) assess acceptability: Use mixed methods (quantitative surveys and qualitative interviews) to evaluate and refine the tools for usability and cultural/linguistic appropriateness, and (3) test effectiveness: Conduct a randomized controlled trial to assess the intervention's impact on urine contamination rates, antibiotic prescribing, and patient satisfaction.

Waitlist Available
Has No Placebo

Baylor College of Medicine

Larissa Grigoryan, MD, PhD

Image of UPMC Magee-Womens Hospital in Pittsburgh, United States.

Catheterization Methods for Postpartum Urinary Problems

18+
All Sexes
Pittsburgh, PA

At least ten percent of patients have postpartum urinary retention or difficulty urinating after birth, which can cause incontinence and other urinary problems long-term. After getting an epidural placed, patients should be numb in their pelvic region. This numbness makes it difficult to feel the need to urinate, so patients need a urinary catheter placed to empty the bladder. Some patients have one catheter placed throughout their labor and others have a catheter placed to empty the bladder then removed every few hours. The investigators are studying whether placing a catheter once or catheterizing multiple times affects the rate of postpartum urinary problems and infection.

Waitlist Available
Has No Placebo

UPMC Magee-Womens Hospital

Anna Binstock, MD

Image of University of California, San Francisco in San Francisco, United States.

Trimethoprim-Sulfamethoxazole for Urinary Tract Infections

13 - 29
All Sexes
San Francisco, CA

The goal of this clinical trial is to learn if a common antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX) can help prevent urinary tract infections (UTIs) in children and young adults who recently had a kidney transplant. Most people take TMP-SMX for about 6 months after getting a kidney transplant. In this study, researchers want to see what happens if people keep taking it for 6 more months. The main questions this study is asking are: * Does TMP-SMX lower the number of UTIs in the first year after transplant? * What side effects or problems do participants have while taking TMP-SMX? Researchers will compare TMP-SMX to a placebo (a look-alike pill that does not contain any medication) to see if TMP-SMX works to prevent UTIs. Participants will: * Take either TMP-SMX or a placebo pill by mouth every day for 6 months * Have three visits to touch base with the study team about any issues * Complete short monthly online surveys about any symptoms or side effects * Share blood and urine test results from their regular transplant clinic visits

Phase 4
Waitlist Available

University of California, San Francisco

Alexandra Bicki, MD

Have you considered Oracea clinical trials?

We made a collection of clinical trials featuring Oracea, we think they might fit your search criteria.
Go to Trials
Image of Children's Community Pediatrics Brentwood in Pittsburgh, United States.

AI Diagnostic Support for Ear Infections

6 - 24
All Sexes
Pittsburgh, PA

Ear infections are common in young children with cold symptoms, but they can be difficult to diagnose due to small ear canals, child movement, and limited viewing time. In this study, investigators will take photos of the eardrums of children 6-24 months of age with upper respiratory symptoms. The photos will be reviewed by imaging software enhanced with artificial intelligence (AI app) to determine whether the AI app changes how ear infections are diagnosed and treated. The AI app has undergone rigorous study and was found to be highly accurate; but how using this technology affects the diagnosis and treatment by clinicians has not been studied. This research may help improve diagnostic accuracy for ear infections and ensure antibiotics are prescribed only for those children who have definite ear infections.

Recruiting
Has No Placebo

Children's Community Pediatrics Brentwood (+1 Sites)

Timothy R Shope, MD, MPH

Merck Sharp & Dohme LLC

Image of Atlantic Health in Morristown, United States.

Methenamine for Urinary Tract Infection

18 - 100
Female
Morristown, NJ

Stress urinary incontinence (SUI) affects at least 40% of women in the United States. Synthetic polypropylene mid-urethral slings (MUS) are the gold standard treatment for SUI. Post-operative urinary tract infections (UTI) are one of the most common complications after MUS placement. Some studies have demonstrated that MUS placement can increase the risk of UTI up to 21-34%. Post-operative UTI can lead to significant healthcare and patient burden. This additional burden further contributes to an estimated annual cost of $1.6 billion for UTI management in the United States. With increased antibiotic usage, there is simultaneous increase in bacterial resistance leading to treatment refractory UTI. The investigators prescribe post-operative antibiotics prophylactically for 3 days after MUS placement with or without concurrent pelvic reconstructive surgery based on prior literature recommending post-operative prophylaxis. There is a greater emphasis on limiting antibiotic use given the trend of development of bacterial resistance. There are studies supporting alternatives such as methenamine for recurrent UTI prophylaxis treatment, but there are limited studies evaluating methenamine for UTI prophylaxis after MUS.

Recruiting
Has No Placebo

Atlantic Health

Image of University of Pennsylvania Primary Care Practice in Philadelphia, United States.

Rapid Testing for Upper Respiratory Tract Infection

18+
All Sexes
Philadelphia, PA

The goal of this study is to understand the use of point of care (POC) testing devices in primary care offices to help clinicians diagnose and appropriately treat patients who have symptoms of upper respiratory infections (URIs). The study will use the BIOFIRE® SPOTFIRE® Respiratory (R) Panel testing device, which is FDA-cleared and CLIA-Waived. This panel can identify up to 15 different viruses and bacteria that can cause URIs. These POC devices will be installed in primary care clinics within the University of Pennsylvania Health System. Patients who come to the clinic with cold-like symptoms (runny nose, cough) will be offered the test. If the patient agrees to the test, their clinician will use a swab to take a small sample of fluid from their nose. This swab will then be tested within the POC device and results will be available within 15 minutes. The results of this sample will be shared with the patient, and their clinician can use the results to help decide the most appropriate medical treatment for the patient. Patients who agree to take the test will be asked to answer a short survey about the test and their experience. Clinicians will also be surveyed to share their thoughts with using the test in their clinics. Focus groups of practice staff and clinicians will also be conducted to understand any potential challenges for using this test in practice. Results from the tests and the surveys will help researchers understand the value of the test to support antibiotic stewardship efforts in primary care clinic settings.

Waitlist Available
Has No Placebo

University of Pennsylvania Primary Care Practice

Have you considered Oracea clinical trials?

We made a collection of clinical trials featuring Oracea, we think they might fit your search criteria.
Go to Trials